Skip to content

Trial Objectives


Image-EXT-071-528-(1).jpgThis trial aims to learn if an investigational medication, called AR-501, is a safe and effective treatment for adults with CF who have Pseudomonas infection. Researchers are hoping AR-501 will stop the growth and spread of bacteria because of the anti-infective properties and different mechanisms of action compared to other antibiotics. The medication is given through a nebulizer, and participants will be randomly assigned to receive the investigational medication or the placebo.

Who Can Participate


Adults with cystic fibrosis who consistently have Pseudomonas infection.

Age: 18+ Gender Any

Estimated Time Commitment


10 visits over 2 months

Time Commitment Details


Visits vary in length with the longest ones taking 3 hours.

Payment & Reimbursement


Payment Provided

Travel Reimbursement Available

Trial Contact


For more information, contact:

Samantha Johnson
303.270.2598

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


Aridis Pharmaceuticals

Principal Investigators

Jane E. Gross

Jane E. Gross, MD, PhD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required